The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

Trial Profile

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2017 Planned number of patients changed from 20 to 40.
    • 15 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 15 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top